COMMON STI571: A COST-EFFECTIVE ALTERNATIVE?

The introduction of common imatinib represents a substantial opportunity for patients battling chronic myeloid leukemia and other conditions. Original brand-name imatinib, often referred to as Gleevec, carries a steep price tag, frequently making it accessibility for some individuals. Off-brand v